A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer

NCT00355238 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

137

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: brivanib (active)

Sponsor

Bristol-Myers Squibb